Screener
Enliven Therapeutics ELVN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Maturities of marketable securities | 108,363 | 60,672 |
| Purchases of marketable securities | (65,837) | (59,225) |
| Purchases of property and equipment | — | (20) |
| Net cash provided by investing activities | 42,526 | 1,427 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 10,053 | 234 |
| Net cash provided by financing activities | 10,053 | 234 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 33,288 | (22,466) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's investing cash flow?
- Enliven Therapeutics (ELVN) reported investing cash flow of $42.53M in Q1 2026.
- How has Enliven Therapeutics's investing cash flow changed year-over-year?
- Enliven Therapeutics's investing cash flow increased by 2880.1% year-over-year, from $1.43M to $42.53M.
- What is the long-term trend for Enliven Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Enliven Therapeutics's investing cash flow has grown at a 968.2% compound annual growth rate (CAGR), from -$1.63M to -$186.22M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Enliven Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude